Bogolepova A N
Pirogov Russian National Research Medical University, Moscow, Russia.
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(8):133-139. doi: 10.17116/jnevro2020120081133.
Vascular cognitive impairment (VCI) is one of the most serious problems of clinical neurology, being the second most common cause of dementia. VCI covers a range of disorders in which vascular factors cause or contribute to cognitive decline. Among the main risk factors for VCI are old age and vascular factors, which lead to endothelial dysfunction and damage, which, in turn, can cause neurovascular dysfunction, increased permeability of the blood-brain barrier, and microvascular thrombosis. Oxidative stress is one of the most important mechanisms for the development of VCI that indicates the need for the use of agents with antioxidant activity. One of these drugs is ethylmethylhydroxypyridine succinate (mexidol). Mexidol is a drug with marked antioxidant and antihypoxic activities. The clinical efficacy of mexidol in relation to VCI has been demonstrated in many studies.
血管性认知障碍（VCI）是临床神经病学中最严重的问题之一，是痴呆症的第二大常见病因。VCI涵盖一系列疾病，其中血管因素导致或促成认知能力下降。VCI的主要危险因素包括老年和血管因素，这些因素会导致内皮功能障碍和损伤，进而可引起神经血管功能障碍、血脑屏障通透性增加和微血管血栓形成。氧化应激是VCI发生发展的最重要机制之一，这表明需要使用具有抗氧化活性的药物。其中一种药物是琥珀酸乙甲羟吡啶（美西多芬）。美西多芬是一种具有显著抗氧化和抗缺氧活性的药物。许多研究已证明美西多芬对VCI的临床疗效。
